Mitsubishi Tanabe Pharma, for possibly more than 500 billion yen, equivalent to $3.21 billion, the person said. Bain Capital has been riding a growing wave of Japanese mergers and acquisitions in ...

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

US private equity firm Bain Capital has agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit Mitsubishi Tanabe ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), setting up one of the largest private equity buyouts in Japan's healthcare ...

Bain Capital LP has entered into a definitive agreement with ... Following the closing of the transaction, Tanabe Pharma will continue to develop innovative medical technologies to enhance research ...

HONG KONG] Bain Capital is looking to raise billions of US dollars for its next Asia fund and a special situation fund in the region, as it moves to back private equity (PE) and credit deals in ...

Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease.